SYGNIS AG

euro adhoc: LION bioscience AG
Strategic management decisions
LION bioscience sells bioinformatics business, Dr. Thure Etzold resigns as CEO

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@

04.04.2006

Ad-hoc Release

LION bioscience sells bioinformatics business Dr. Thure Etzold resigns as CEO

Heidelberg, April 4, 2006 - LION bioscience AG today  announced  the successful completion of the sales process regarding its bioinformatics business.

As of April 4, 2006 the bioinformatics business, consisting of the subsidiaries LION Bioscience  Ltd,  Cambridge  UK  and  LBAV  Inc., Cambridge,  MA,  USA  is transferred to BioWisdom Ltd., Cambridge, UK. The sales price is up to 4 Mio  E.

In this context, Dr. Thure Etzold, original inventor of the SRS technology  and current CEO of LION, will resign from the LION board as  of  April  4,  2006  as planned.

For further information, please contact:

|Peter Willinger                                      |
|Chief Financial Officer                         |
|Tel: +49 (0) 6221-4038 293                    |
|Email:                                                    |
|peter.willinger@lionbioscience.com        |
###

Except for the historical information contained herein, the  matters set  forth in this press release are forward looking. These forward-looking statements  may include  projections,  assumptions, estimates,  targets,  and  descriptions  of future events. Such statements are based on currently available information  and on LION's current expectations as to future events that  may  not  prove to  be accurate. These statements are not guarantees of future performance and  involve risks and uncertainties that are difficult to predict. Many factors could  cause the actual results, performance  or  achievements  of  LION  to  be  materially different from those that may be projected,  expected,  targeted,  expressed or implied by such statements. All roll-out plans and future dates with respect  to completion of development and market release of LION products are  target  dates only based on the company's current planning and may change in the  future.  Any delays in the current product release schedule will have  a  materially  adverse effect on the company's targets for fiscal year. ###

@@start.t2@@end of announcement                                                 euro adhoc 04.04.2006 15:11:53
--------------------------------------------------------------------------------@@end@@

ots Originaltext: LION Bioscience AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Stephan Trautvetter
Director Finance & Accounting
Telefon: +49(0)6221 4038 476
E-Mail: stephan.trautvetter@lionbioscience.com

Branche: Biotechnology
ISIN:      DE0005043509
WKN:        504350
Index:    CDAX, Prime All Share, Technologie All Share
Börsen:  Frankfurter Wertpapierbörse / regulated dealing/prime
              standard
              New York / ADR
              Börse Berlin-Bremen / free trade
              Hamburger Wertpapierbörse / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Niedersächsische Börse zu Hannover / free trade
              Bayerische Börse / free trade



Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: